Home
|
Help
|
Contact
Sign in
WPRIM Management System>
DCMS
>
Acta Pharmaceutica Sinica
>
2019
>
54
>
10
Volume:
54
Issue:
10
1. The roles of m
6
A in cancer biology and its targeted therapy
Page:1771—1782
2. Mechanisms of metabolite-triggered oncogenic signaling in cancer
Page:1755—1770
3. Advances of microenvironment-activated nanosized drug delivery system for cancer immunotherapy
Page:1802—1809
4. Advanced research and technology development of antibody-drug conjugates
Page:1810—1817
5. Advances in hyperprogressive disease of PD-1/PD-L1 antibody drugs and rational drug therapy
Page:1735—1740
6. Non-coding RNA and tumor immune regulation
Page:1783—1791
7. Research progress in immunotherapy for glioblastoma
Page:1792—1801
8. The mechanism and research progress of drug resistance of PD-1/PD-L1 immunotherapy in tumors
Page:1728—1734
9. Research progress of tumor immune and tumor metabolic drug targets
Page:1718—1727
10. Review on clinical research progress of immunotherapy in liver cancer
Page:1749—1754
11. Construction and anti-tumor efficacy of a peptide vaccine that targets calcium-binding protein S100A9
Page:1837—1844
12. Mechanistic advancement in chemotherapeutic agents modulated antitumor immune response
Page:1741—1748
13. Research progress of dendritic cells anti-tumor vaccine stimulated by mRNA
Page:1818—1823
14. The antitumor activity of STAT3 target inhibitor Bt354 andmolecular mechanism of anti-prostate cancer
Page:1851—1857
15. The effects of different stimulators on the activation of human lymphocytes
Page:1863—1867
16. Research advancement of succinyl-CoA transferase SCOT in tumor metabolism
Page:1831—1836
17. DEPTOR improves cisplatin chemosensitivity in esophageal squamous cell carcinoma cells by inducing Caspase-1-mediated pyroptosis
Page:1845—1850
18. Research progress of carnitine palmitoyltransferase 1in tumor immunotherapy
Page:1824—1830
19. Post-translational modifications of proteins and cancer immunotherapy
Page:1711—1717
20. Establishment and optimization of an enzyme-cell based high-throughput screening platform for IDO1 inhibitors
Page:1868—1874
21. The optimization and application of cell-based screening model for IL-17-mediated signaling pathway
Page:1858—1862
22. Establishment and application of STING agonist
in
-
vitro
screening model
Page:1875—1880